<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615455</url>
  </required_header>
  <id_info>
    <org_study_id>2020-002804-38</org_study_id>
    <nct_id>NCT04615455</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome</brief_title>
  <acronym>AMASS</acronym>
  <official_title>A Randomized Clinical Trial Evaluating Allogeneic Adipose-derived MesenchymAl Stem Cells as a Treatment of Dry Eye Disease in Patients With Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AMASS is a double-blinded randomized clinical trial with the purpose of investigating whether&#xD;
      injection of allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland&#xD;
      (LG) results in increased ocular comfort compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMASS is a double-blinded randomized clinical trial which will be performed at the Department&#xD;
      of Ophthalmology, University Hospital of Copenhagen, Denmark. 40 patients with severe aqueous&#xD;
      deficient dry eye disease (ADDE) due to Sjögren's Syndrome (SS) will be recruited from the&#xD;
      Dept. of Ophthalmology, Rigshospitalet, and allocated in ratio 1:1 to either injection of&#xD;
      allogeneic adipose-derived mesenchymal stem cells (ASCs) or placebo (vehicle, Crystore CS10)&#xD;
      into the lacrimal gland (LG) in one eye. We hypothesize that injection of allogeneic ASCs&#xD;
      into the LG increases tear production and reduce inflammation resulting in increased ocular&#xD;
      comfort compared to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>The OSDI is a valid and reliable instrument for measuring dry eye disease severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-invasive keratography tear break-up time (NIKBUT)</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>As measured with the Keratograph 5M (Oculus™)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear meniscus height (TMH)</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>As measured with the Keratograph 5M (Oculus™)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's I test</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>Change in tear production as evaluated with the Schirmer's I test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear osmolarity</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>Change in tear osmolarity measured with TearLab™</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford scale</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>Change in staining of the ocular surface (grade 0-5 with 0 being absent corneal staining and 5 being severe corneal staining)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA anti-bodies</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>Development of anti-human leucocyte antigen (HLA) anti-bodies evaluated with Luminex HLA anti-body screening&#xD;
Development of anti-HLA anti-bodies evaluated with Luminex HLA anti-body screening&#xD;
Development of donor-specific HLA-antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Keratoconjunctivitis Sicca, in Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Adipose tissue-derived mesenchymal stem cells (ASCs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One transconjunctival injection of allogeneic ASCs into the LG in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle, Cryostor CS10)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One transconjunctival injection of Cryostor CS10 into the LG in one eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASCs</intervention_name>
    <description>ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.</description>
    <arm_group_label>Adipose tissue-derived mesenchymal stem cells (ASCs)</arm_group_label>
    <other_name>Allogeneic adipose-derived mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cryostor CS10</intervention_name>
    <description>CryoStor® CS10 freeze medium</description>
    <arm_group_label>Placebo (vehicle, Cryostor CS10)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Sjögren's syndrome according to the 2016 American College of&#xD;
             Rheumatology/European League Against Rheumatism classification criteria for primary&#xD;
             Sjögren's syndrome&#xD;
&#xD;
          -  OSDI-score ≥ 33&#xD;
&#xD;
          -  Schirmer's test 1-5 mm/5 minutes&#xD;
&#xD;
          -  NIKBUT &lt; 10 sec&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  LG volume on MRI &lt; 0,2 cm3 in the study eye&#xD;
&#xD;
          -  Previous treatment with ASCs or other stem cell products in the LG(s)&#xD;
&#xD;
          -  Reduced immune response (e.g. HIV positive)&#xD;
&#xD;
          -  Pregnancy or planned pregnancy within the next 2 years&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Topical treatment with eye drops other than to treat dry eye disease (DED)&#xD;
&#xD;
          -  Any other disease/condition judged by the investigator to be grounds for exclusion,&#xD;
             such as infection in or around the eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Heegaard, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Møller-Hansen, MD</last_name>
    <phone>+4593901230</phone>
    <email>moller.hansen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>DK</state>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Møller-Hansen, MD</last_name>
      <phone>28738771</phone>
      <email>moller.hansen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Michael Møller-Hansen</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

